ClinicalTrials.gg
Active, not recruitingNCT05346354Updated Jun 24, 2026

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

A Phase 2/3 interventional study of Ravulizumab in Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 16 sites in 7 countries. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Neuromyelitis Optica by AstraZeneca — 3 open to participants now, 5 under way, 3 of them phase 3. Neuromyelitis Optica · AstraZeneca.

Started
2022
the only one that year
Phase 2/3
3 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Neuromyelitis Optica by AstraZeneca, this one is the only one that started in 2022, is one of 3 in phase 2/3, and was the 6th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

3 of the 11 studies in Neuromyelitis Optica by AstraZeneca are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Neuromyelitis Optica by AstraZeneca, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder

Browse trials for

Keywords

  • Neuromyelitis Optica Spectrum Disorder
  • Ravulizumab
  • ALXN1210
  • CNS Autoimmune Disorders
  • NMO
  • NMOSD
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be anti-AQP4 Ab-positive and have a diagnosis of NMOSD as defined by the 2015 international consensus diagnostic criteria.
  • Complement inhibitor treatment-naïve participants must have had at least 1 attack or relapse in the last 12 months prior to the Screening Period.
  • Expanded Disability Status Scale (EDSS) score ≤ 7.
  • Eculizumab-experienced participants must be clinically stable per Investigator for 30 days and have been treated with eculizumab in Study ECU-NMO-303 for at least 90 days prior to screening with no missed doses within 2 months prior to Day 1.
  • Participants who enter the study receiving supportive IST(s) (eg, , azathioprine [AZA], mycophenolate mofetil [MMF], methotrexate [MTX], tacrolimus [TAC], cyclosporin [CsA], or cyclophosphamide [CYC]) for the prevention of relapse, either in combination or monotherapy, must be on a stable dosing regimen of adequate duration prior to Screening and remain on a stable dosing regimen during the Screening Period.
  • To reduce the risk of meningococcal infection (Neisseria meningitidis), all participants must be vaccinated against meningococcal infection.
  • Documented vaccination for Hib and S pneumoniae at least 14 days prior to Day 1 according to national/local guidelines for the applicable age group.

Exclusion criteria

Exclusion Criteria:

  • Use of rituximab within 3 months prior to screening.
  • Currently treated with a biologic medications (other than eculizumab) that may affect immune system functioning, or has stopped treatment with a biologic medication that may affect immune system functioning, and 5 half lives of the medication have not elapsed by the time of the Screening Visit.
  • Use of intravenous immunoglobulin (IVIg) or plasma exchange (PE) within 3 weeks prior to Screening.
  • Participation in another drug or investigational device study (other than Study ECU-NMO-303) within 5 half lives of that investigational product (if known) or 30 days before initiation of the first dose of study drug, whichever is longer.
  • Use of immunomodulatory therapies for multiple sclerosis within 3 months prior to Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    During the Primary Treatment Period, all participants will receive weight-based dosing of ravulizumab IV for a total of 50 weeks of treatment. During the Extension Period, participants will continue to receive weight-based dosing of ravulizumab IV for up to 104 weeks.

    Drug: Ravulizumab

Interventions

  • Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight. During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight.

    Also known as: ALXN1210, Ultomiris

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Annualized Relapse Rate at Week 50

    Time frame: Baseline, Week 50

  2. Time to First Adjudicated On-trial Relapse through Week 50

    Time frame: Baseline through Week 50

Secondary outcomes

  1. Change From Baseline in Expanded Disability Status Scale Score At Week 50

    The score ranges are 0 to 10, higher score indicates worse outcome.

    Time frame: Baseline, Week 50

  2. Change From Baseline in Hauser Ambulation Index at Week 50

    The score ranges are 0 to 9, higher score indicates worse outcome.

    Time frame: Baseline, Week 50

  3. Change From Baseline in Visual Acuity at Week 50

    Time frame: Baseline, Week 50

  4. Change From Baseline in Confrontational Visual Fields at Week 50

    Time frame: Baseline, Week 50

  5. Change From Baseline in Color Vision at Week 50

    Time frame: Baseline, Week 50

  6. Serum Ravulizumab Concentration

    Time frame: Predose and postdose (at end of infusion) on Day 1, Weeks 2, 10, 18, 26, and 42, and predose on Week 50

  7. Change from Baseline in Free Serum Complement Component 5 (C5) Concentration Over Time Through Week 50

    Time frame: Baseline through Week 50

07

Study locations

16 sites
  • Research Site
    Washington D.C., District of Columbia 20010, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Edmonton, Alberta T6G 1C9, Canada
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Montreal, Quebec H3T1C5, Canada
  • Research Site
    Le Kremlin-Bicêtre, 94270, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Chieti, 66013, Italy
  • Research Site
    Gallarate, 21013, Italy
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Yokohama, 232-0024, Japan
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Esplugues de Llobregat, 8950, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Jun 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 26, 2022
StartActual
Jun 23, 2022
Primary completionEst.
Jun 22, 2026
CompletionEst.
Mar 30, 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05346354
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Jun 23, 2022
Primary completion
Jun 22, 2026 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Jun 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion